WO2014044794A3 - Pharmaceutical composition - Google Patents
Pharmaceutical composition Download PDFInfo
- Publication number
- WO2014044794A3 WO2014044794A3 PCT/EP2013/069570 EP2013069570W WO2014044794A3 WO 2014044794 A3 WO2014044794 A3 WO 2014044794A3 EP 2013069570 W EP2013069570 W EP 2013069570W WO 2014044794 A3 WO2014044794 A3 WO 2014044794A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- treatment
- activated carbon
- provides
- oral administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380060120.4A CN104797243A (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical composition |
CA2885278A CA2885278A1 (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical composition |
JP2015532423A JP6456830B2 (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical composition |
EP13771084.4A EP2897594B1 (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical composition |
US14/429,806 US10449158B2 (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical activated carbon composition |
ES13771084T ES2801801T3 (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical composition |
DK13771084.4T DK2897594T3 (en) | 2012-09-21 | 2013-09-20 | PHARMACEUTICAL COMPOSITION |
US14/779,412 US9682101B2 (en) | 2013-03-25 | 2014-03-25 | Composition for the treatment of disease |
PCT/EP2014/055937 WO2014154677A1 (en) | 2013-03-25 | 2014-03-25 | Composition for the treatment of disease |
EP14713807.7A EP2978413A1 (en) | 2013-03-25 | 2014-03-25 | Composition for the treatment of disease |
US15/598,819 US20170319617A1 (en) | 2013-03-25 | 2017-05-18 | Composition for the treatment of disease |
US16/123,175 US20190134081A1 (en) | 2013-03-25 | 2018-09-06 | Composition for the treatment of disease |
US17/117,599 US11712422B2 (en) | 2012-09-21 | 2020-12-10 | Pharmaceutical compositions comprising activated carbon |
US18/208,658 US20240016753A1 (en) | 2012-09-21 | 2023-06-12 | Pharmaceutical compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12185339 | 2012-09-21 | ||
EP12185339.4 | 2012-09-21 | ||
EP13160799 | 2013-03-25 | ||
EP13160799.6 | 2013-03-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/429,806 A-371-Of-International US10449158B2 (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical activated carbon composition |
US201916657038A Continuation | 2012-09-21 | 2019-10-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014044794A2 WO2014044794A2 (en) | 2014-03-27 |
WO2014044794A3 true WO2014044794A3 (en) | 2014-06-19 |
Family
ID=49293599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/069570 WO2014044794A2 (en) | 2012-09-21 | 2013-09-20 | Pharmaceutical composition |
Country Status (8)
Country | Link |
---|---|
US (3) | US10449158B2 (en) |
EP (1) | EP2897594B1 (en) |
JP (1) | JP6456830B2 (en) |
CN (2) | CN111053759A (en) |
CA (1) | CA2885278A1 (en) |
DK (1) | DK2897594T3 (en) |
ES (1) | ES2801801T3 (en) |
WO (1) | WO2014044794A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6456830B2 (en) * | 2012-09-21 | 2019-01-23 | フェリング ベスローテン フェンノートシャップ | Pharmaceutical composition |
US9682101B2 (en) | 2013-03-25 | 2017-06-20 | Ferring B.V. | Composition for the treatment of disease |
CN105362496A (en) * | 2015-06-13 | 2016-03-02 | 国网山东省电力公司临沂供电公司 | Protection product for treating electric ophthalmia of electric power staff |
JPWO2017073531A1 (en) * | 2015-10-26 | 2018-08-09 | 第一三共株式会社 | Delivery preparation of porous material to large intestine or lower intestine |
WO2018063216A1 (en) * | 2016-09-29 | 2018-04-05 | M Pharmaceutical Usa Inc. | Dual compartment capsule for the administration of orlistat |
GB2569119A (en) * | 2017-12-05 | 2019-06-12 | Rainbow Valley Nutrients Ltd | An aqueous beverage containing microencapsulated food supplement |
AU2019320483A1 (en) | 2018-08-05 | 2021-02-18 | Da Volterra | Compositions for the treatment of graft versus host disease |
AU2019317986A1 (en) | 2018-08-05 | 2021-02-11 | Da Volterra | Method for improving anticancer agent efficacy |
EP3610860A1 (en) | 2018-08-15 | 2020-02-19 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen | Composition of carbon dioxide absorbent or adsorbent, whereby the said composition contains a polymeric coating selected from silicone rubber and cellulose |
DE102021127957A1 (en) | 2021-10-27 | 2023-04-27 | Rheinisch-Westfälische Technische Hochschule Aachen, Körperschaft des öffentlichen Rechts | Coated drug formulation for controlled in vivo uptake of CO2 |
CA3235110A1 (en) * | 2021-10-27 | 2023-05-04 | Stefan Jockenhovel | Coated active ingredient formulation for controlled in-vivo uptake of co2 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022096A1 (en) * | 1996-11-15 | 1998-05-28 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US20010051150A1 (en) * | 1999-04-30 | 2001-12-13 | Natarajan Ranganathan | Compositions and methods for alleviating symptoms of uremia in patients |
WO2011104275A1 (en) * | 2010-02-23 | 2011-09-01 | Da Volterra | Formulations for oral delivery of adsorbents in the gut |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5489010A (en) * | 1977-12-27 | 1979-07-14 | Kureha Chem Ind Co Ltd | Spherical activated charcoal antidote |
IT1230576B (en) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | ORAL PHARMACEUTICAL FORMULATIONS WITH SELECTIVE LIBERATION IN THE COLON |
US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
US20040166248A1 (en) * | 2000-12-15 | 2004-08-26 | Sheng-Hsin Hu | Coated activated carbon |
US7163696B2 (en) * | 2001-10-11 | 2007-01-16 | Pfizer Inc. | Pharmaceutical formulations |
US8048413B2 (en) * | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
US8110186B2 (en) * | 2006-09-18 | 2012-02-07 | Chelatexx, LLC | Method to maintain the efficacy of orlistat |
US7955622B2 (en) * | 2006-10-13 | 2011-06-07 | Actavis Group Ptc Hf | Controlled-release galantamine formulations |
WO2009049239A1 (en) | 2007-10-12 | 2009-04-16 | Ocera Therapeutics, Inc. | Use of adsorbent carbon microspheres to treat pouchitis |
TWI643623B (en) | 2011-10-03 | 2018-12-11 | 菲瑞茵公司 | Composition for the treatment of fistula |
JP6456830B2 (en) * | 2012-09-21 | 2019-01-23 | フェリング ベスローテン フェンノートシャップ | Pharmaceutical composition |
US9682101B2 (en) * | 2013-03-25 | 2017-06-20 | Ferring B.V. | Composition for the treatment of disease |
-
2013
- 2013-09-20 JP JP2015532423A patent/JP6456830B2/en active Active
- 2013-09-20 WO PCT/EP2013/069570 patent/WO2014044794A2/en active Application Filing
- 2013-09-20 US US14/429,806 patent/US10449158B2/en active Active
- 2013-09-20 DK DK13771084.4T patent/DK2897594T3/en active
- 2013-09-20 CA CA2885278A patent/CA2885278A1/en active Pending
- 2013-09-20 CN CN201911389038.1A patent/CN111053759A/en active Pending
- 2013-09-20 ES ES13771084T patent/ES2801801T3/en active Active
- 2013-09-20 CN CN201380060120.4A patent/CN104797243A/en active Pending
- 2013-09-20 EP EP13771084.4A patent/EP2897594B1/en active Active
-
2020
- 2020-12-10 US US17/117,599 patent/US11712422B2/en active Active
-
2023
- 2023-06-12 US US18/208,658 patent/US20240016753A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022096A1 (en) * | 1996-11-15 | 1998-05-28 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US20010051150A1 (en) * | 1999-04-30 | 2001-12-13 | Natarajan Ranganathan | Compositions and methods for alleviating symptoms of uremia in patients |
WO2011104275A1 (en) * | 2010-02-23 | 2011-09-01 | Da Volterra | Formulations for oral delivery of adsorbents in the gut |
Also Published As
Publication number | Publication date |
---|---|
US11712422B2 (en) | 2023-08-01 |
JP6456830B2 (en) | 2019-01-23 |
US10449158B2 (en) | 2019-10-22 |
EP2897594B1 (en) | 2020-04-08 |
CA2885278A1 (en) | 2014-03-27 |
CN111053759A (en) | 2020-04-24 |
WO2014044794A2 (en) | 2014-03-27 |
DK2897594T3 (en) | 2020-06-29 |
US20240016753A1 (en) | 2024-01-18 |
US20210196647A1 (en) | 2021-07-01 |
US20150245999A1 (en) | 2015-09-03 |
ES2801801T3 (en) | 2021-01-13 |
JP2015529233A (en) | 2015-10-05 |
EP2897594A2 (en) | 2015-07-29 |
CN104797243A (en) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014044794A3 (en) | Pharmaceutical composition | |
IL233154A (en) | Compounds, pharmaceutical compositions comprising the same and uses thereof | |
NZ730763A (en) | Methods of treating a tauopathy | |
EP3065808A4 (en) | Devices and methods for continuous drug delivery via the mouth | |
IL223783B (en) | Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament | |
EP3072506A4 (en) | Carrier for drug delivery and conjugate, composition containing same, and method for administering same | |
PT2726141T (en) | Device, system and methods for the oral delivery of therapeutic compounds | |
GB201106750D0 (en) | Novel compounds | |
PL2672966T3 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
PT2729151T (en) | Pharmaceutical composition, methods for treating and uses thereof | |
WO2010083385A3 (en) | Compounds for reducing drug resistance and uses thereof | |
HUE037747T2 (en) | Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them | |
SI2739615T1 (en) | Phenyl-3-aza-bicyclo(3.1.0)hex-3-yl-methanones and the use thereof as medicament | |
EP2978423A4 (en) | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it | |
WO2012103810A1 (en) | Certain chemical entities, compositions, and methods | |
HUE045625T2 (en) | Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract | |
EP2924042A4 (en) | Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof | |
EP3213746A4 (en) | Pharmaceutical composition for oral administration comprising taxane | |
EP2889307A4 (en) | Alpha-conotoxin peptide, and medical composition and purpose thereof | |
EP3020417A4 (en) | Pharmaceutical composition for respiratory administration | |
EP2601955A4 (en) | Adsorbent for oral administration, method for producing same, and drug using same | |
HK1206599A1 (en) | Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection hpv | |
IL237688A0 (en) | Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, methods for the production thereof and use of same | |
EP2929786A4 (en) | Composition comprising natural polyphenol compounds, and composition for oral administration comprising same | |
EP2784061A4 (en) | Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13771084 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2885278 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015532423 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14429806 Country of ref document: US |